Back to top
more

Neurocrine Biosciences (NBIX)

(Real Time Quote from BATS)

$126.88 USD

126.88
238,166

-2.03 (-1.58%)

Updated Aug 4, 2025 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

by Zacks Equity Research

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for December 9th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Neurocrine Biosciences (NBIX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

Zacks Equity Research

New Strong Sell Stocks for October 19th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Zacks Equity Research

New Strong Sell Stocks for October 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks.com featured highlights include: MarketAxess, Domino's Pizza and Neurocrine Biosciences

by Zacks Equity Research

Zacks.com featured highlights include: MarketAxess, Domino's Pizza and Neurocrine Biosciences

Zacks Equity Research

3 Stocks With Momentum Anomaly to Buy This Earnings Season

by Zacks Equity Research

These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of the opportunity.

Zacks Equity Research

MediWound (MDWD) Jumps: Stock Rises 9.4%

by Zacks Equity Research

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY

by Zacks Equity Research

The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY

Manaswita Ghosh Dutta headshot

3 Stocks to Buy on New Drug Approvals by FDA

by Manaswita Ghosh Dutta

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

Zacks Equity Research

AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding

by Zacks Equity Research

The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.

Zacks Equity Research

Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?